What is treatment free remission in chronic myeloid leukemia?
作者信息
Rea Delphine, Etienne Gabriel, Mahon François-Xavier
机构信息
Institut Bergonie Cancer Center, Department of Hematology, Universite Bordeaux, Bordeaux, Aquitaine, France.
出版信息
Oncotarget. 2017 Dec 18;9(4):4279. doi: 10.18632/oncotarget.23398. eCollection 2018 Jan 12.
Abstract
摘要
相似文献
1
What is treatment free remission in chronic myeloid leukemia?慢性髓性白血病中的无治疗缓解是什么？
Oncotarget. 2017 Dec 18;9(4):4279. doi: 10.18632/oncotarget.23398. eCollection 2018 Jan 12.
2
Inclusion body myositis in a patient with chronic myeloid leukemia treated with dasatinib: a case report.达沙替尼治疗慢性髓性白血病患者并发包涵体肌炎：一例报告
J Med Case Rep. 2015 Sep 16;9:214. doi: 10.1186/s13256-015-0674-9.
3
Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia.酪氨酸激酶抑制剂的停药和靶向白血病干细胞的新方法：无治疗缓解作为慢性髓性白血病的新目标。
Cancer Lett. 2014 May 28;347(1):22-8. doi: 10.1016/j.canlet.2014.01.033. Epub 2014 Feb 4.
4
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.BCR-ABL酪氨酸激酶特异性抑制剂在伴有费城染色体的慢性髓性白血病急变期和急性淋巴细胞白血病中的活性
N Engl J Med. 2001 Apr 5;344(14):1038-42. doi: 10.1056/NEJM200104053441402.
5
[Imatinib therapy in chronic myeloid leukemia].[伊马替尼治疗慢性粒细胞白血病]
Orv Hetil. 2008 Aug 10;149(32):1509-12. doi: 10.1556/OH.2008.28354.
6
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.慢性粒细胞白血病中的新型酪氨酸激酶抑制剂
Curr Opin Oncol. 2006 Nov;18(6):578-83. doi: 10.1097/01.cco.0000245314.97638.d3.
7
Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.移植至无治疗缓解：慢性髓系白血病中“治愈”观念的演变
Expert Rev Hematol. 2015 Dec;8(6):785-97. doi: 10.1586/17474086.2015.1087843. Epub 2015 Sep 12.
8
Chronic myeloid leukemia-transplantation in the tyrosine kinase era.酪氨酸激酶时代的慢性髓性白血病移植
Hematol Oncol Clin North Am. 2014 Dec;28(6):1037-53. doi: 10.1016/j.hoc.2014.08.002. Epub 2014 Oct 5.
9
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.酪氨酸激酶抑制剂时代慢性期慢性髓性白血病患者的条件生存情况
Cancer. 2016 Jan 15;122(2):238-48. doi: 10.1002/cncr.29745. Epub 2015 Oct 19.
10
Immunology of chronic myeloid leukemia: current concepts and future goals.慢性髓系白血病的免疫学：当前概念与未来目标
Expert Rev Clin Immunol. 2015 Apr;11(4):511-22. doi: 10.1586/1744666X.2015.1019474. Epub 2015 Mar 2.
引用本文的文献
1
Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.慢性髓性白血病中酪氨酸激酶抑制剂相关血液学不良事件的网络荟萃分析。
Br J Clin Pharmacol. 2019 Oct;85(10):2280-2291. doi: 10.1111/bcp.13933. Epub 2019 May 23.
本文引用的文献
1
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.法国停止伊马替尼（STIM1）研究的慢性髓性白血病患者的长期随访。
J Clin Oncol. 2017 Jan 20;35(3):298-305. doi: 10.1200/JCO.2016.68.2914. Epub 2016 Oct 31.
2
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.慢性髓性白血病患者的预期寿命接近普通人群。
J Clin Oncol. 2016 Aug 20;34(24):2851-7. doi: 10.1200/JCO.2015.66.2866. Epub 2016 Jun 20.
3
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.欧洲白血病网关于慢性髓性白血病治疗管理及不良事件避免的建议
Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Epub 2016 Apr 28.
4
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.达沙替尼在慢性髓性白血病患者中的停药研究，这些患者已维持深度分子反应超过1年（DADI试验）：一项多中心2期试验
Lancet Haematol. 2015 Dec;2(12):e528-35. doi: 10.1016/S2352-3026(15)00196-9. Epub 2015 Nov 10.
5
Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?伊马替尼停药后慢性髓性白血病患者的肌肉骨骼疼痛：一种酪氨酸激酶抑制剂撤药综合征？
J Clin Oncol. 2014 Sep 1;32(25):2821-3. doi: 10.1200/JCO.2014.55.6910. Epub 2014 Jul 28.
6
Pushing the limits of targeted therapy in chronic myeloid leukaemia.慢性髓性白血病靶向治疗的极限探索。
Nat Rev Cancer. 2012 Jul 24;12(8):513-26. doi: 10.1038/nrc3317.
7
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.慢性粒细胞白血病患者在完全分子缓解超过2年后停用甲磺酸伊马替尼。
Blood. 2007 Jan 1;109(1):58-60. doi: 10.1182/blood-2006-03-011239. Epub 2006 Sep 14.
Zotero 插件